Research and Education

Scientific publishing

Research

Scientific publishing

2018

Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients. Lung Cancer.

Falk AT, Yazbeck N, Guibert N, Chamorey E, Paquet A, Ribeyre L, Bence C, Zahaf K, Leroy S, Marquette CH, Cohen C, Mograbi B, Mazières J, Hofman V, Brest P, Hofman P, Ilié M. 

2018 Jul;121:70-75.

Ensuring the Safety and Security of Frozen Lung Cancer Tissue Collections through the Encapsulation of Dried DNA. Cancers (Basel).

Washetine K, Kara-Borni M, Heeke S, Bonnetaud C, Félix JM, Ribeyre L, Bence C, Ilié M, Bordone O, Pedro M, Maitre P, Tanga V, Gormally E, Mossuz P, Lorimier P, Marquette CH, Mouroux J, Cohen C, Lassalle S, Long-Mira E, Clément B, Dagher G, Hofman V, Hofman P. 

2018 Jun 11;10(6).

Use of circulating tumor cells in prospective clinical trials for NSCLC patients - standardization of the pre-analytical conditions. Clin Chem Lab Med.

Ilie M, Hofman V, Leroy S, Cohen C, Heeke S, Cattet F, Bence C, Lalvée S, Mouroux J, Marquette CH, Hofman P; STALKLUNG01 and AIR Study Consortium Investigators.

2018 May 24;56(6):980-989.

Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients. Cancers (Basel).

Heeke S, Hofman V, Long-Mira E, Lespinet V, Lalvée S, Bordone O, Ribeyre C, Tanga V, Benzaquen J, Leroy S, Cohen C, Mouroux J, Marquette CH, Ilié M, Hofman P. 

2018 Mar 21;10(4).

Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients? Cancers (Basel).

Hofman V, Lassalle S, Bence C, Long-Mira E, Nahon-Estève S, Heeke S, Lespinet-Fabre V, Butori C, Ilié M, Hofman P. 

2018 Mar 13;10(3).

Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Annals of Oncology

Ilié M, Szafer-Glusman E, Hofman V, Chamorey E, Lalvée S, Selva E, Leroy S, Marquette CH, Kowanetz M, Hedge P, Punnoose E, Hofman P.

2018 Jan 1;29(1):193-199.

2017

PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted? Expert Rev Mol Diagn. 

Hofman P. 

2017 Dec;17(12):1097-1108

Training the Next Generation of Biobankers: A Two-Year Master ’s Course in the Management of Biobanks.  Biopreservation and Biobanking

Gormally E, Hardy I, Caboux E, di Donato JH, Hainaut P, Hofman P. 

2017 Oct;15(5):438-450

Optimization of EGFR mutation detection by the fully-automated PCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer. Oncotarget.

Ilie M, Butori C, Lassalle S, Heeke S, Piton N, Sabourin JC, Tanga V, Washetine K, Long-Mira E, Maitre P, Yazbeck N, Bordone O, Lespinet V, Leroy S, Cohen C, Mouroux J, Marquette CH, Hofman V, Hofman P. 

2017 Oct 4;8(61):103055-103062

Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities. Curr Mol Med.

Ilie M, Benzaquen J, Hofman V, Lassalle S, Yazbeck N, Leroy S, Heeke S, Bence C, Mograbi B, Glaichenhaus N, Marquette CH, Hofman P.

2017;17(8):527-540.

Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients. Oncotarget.

Ilie M, Szafer-Glusman E, Hofman V, Long-Mira E, Suttmann R, Darbonne W, Butori C, Lalvée S, Fayada J, Selva E, Yu W, Marquette CH, Shames DS, Punnoose E, Hofman P. 

2017 Apr 18;8(16):26112-26121.

Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS One.

Ilie M, Khambata-Ford S, Copie-Bergman C, Huang L, Juco J, Hofman V, Hofman P.

2017 Aug 10;12(8):e0183023.

Liquid biopsy for early detection of lung cancer. Curr Opin Oncol. 

Hofman P. 

2017 Jan;29(1):73-78.

2016

PD-L1 expression in basaloid squamous cell lung carcinoma:
Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome.
Modern Pathology

Ilie M, Falk AT, Butori C, Chamorey E, Bonnetaud C, Long E, Lassalle S, Zahaf K, Vénissac N, Mouroux J, Cohen C, Brambilla E, Marquette CH, Hofman V, Hofman P.

2016 Dec;29(12):1552-1564

Pathologists and liquid biopsies: to be or not to be? Virchows Arch.

Hofman P, Popper HH. 

2016 Dec;469(6):601-609.

High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness. Cancer Med.

Long E, Ilie M, Bence C, Butori C, Selva E, Lalvée S, Bonnetaud C, Poissonnet G, Lacour JP, Bahadoran P, Brest P, Gilson E, Ballotti R, Hofman V, Hofman P. 

2016 Jun;5(6):1022-30.

MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib. Oncotarget.

Lassalle S, Zangari J, Popa A, Ilie M, Hofman V, Long E, Patey M, Tissier F, Belléannée G, Trouette H, Catargi B, Peyrottes I, Sadoul JL, Bordone O, Bonnetaud C, Butori C, Bozec A, Guevara N, Santini J, Hénaoui IS, Lemaire G, Blanck O, Vielh P, Barbry P, Mari B, Brest P, Hofman P.

2016 May 24;7(21):30461-78.

Comparative study of the PDL1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol.

Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvée S, Washetine K, Mouroux J, Vénissac N, Poudenx M, Otto J, Sabourin JC, Marquette CH, Hofman V, Hofman P.

2016 Jan;27(1):147-53.

2015

Genetic and pharmacological inactivation of the purinergic P2RX7 receptor dampens inflammation but increases tumor incidence in a mouse model of colitis-associated cancer. Cancer Res.
Hofman P, Cherfils-Vicini J, Bazin M, Ilie M, Juhel T, Hébuterne X, Gilson E, Schmid-Alliana A, Boyer O, Adriouch S, Vouret-Craviari V. 

2015 Mar 1;75(5):835-45.

For more information, visit the following topics:

PARTNERSHIPS

See more